Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Core Viewpoint - Surrozen, Inc. is advancing its ophthalmology pipeline with a focus on developing novel treatments for severe eye diseases, supported by key leadership appointments and patent issuances [1][4][5]. Business Highlights - The company is leveraging its expertise in Wnt biology and antibody technologies to develop treatments for retinal diseases [2]. - Surrozen's lead candidates, SZN-8141 and SZN-8143, are progressing towards clinical development, with an IND application for SZN-8141 expected in 2026 [5]. Key Events in Second Quarter 2025 - The appointment of Dr. Daniel Chao as Vice President of Clinical Development is expected to enhance the company's clinical capabilities [4]. - The formation of a Clinical Advisory Board consisting of leading retinal specialists aims to guide the clinical development of the ophthalmology pipeline [5]. - Surrozen presented preclinical data for SZN-8141 and SZN-8143 at major conferences, showcasing their potential in promoting retinal vessel regrowth [5]. Financial Highlights - As of June 30, 2025, Surrozen reported cash and cash equivalents of $90.4 million, down from $101.6 million as of March 31, 2025 [6]. - The company achieved a net income of $39.7 million, or $2.55 per share, for the quarter, a significant improvement from a net loss of $25.3 million, or ($7.99) per share, for the same period in 2024 [8]. - Research and development expenses increased to $6.0 million from $5.3 million year-over-year, reflecting higher manufacturing and lab costs [11]. Ophthalmology Pipeline - SZN-8141 is designed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) by combining Frizzled 4 (Fzd4) agonism and VEGF antagonism [9]. - SZN-8143 targets DME, wet AMD, and uveitic macular edema (UME) through a combination of Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism [10]. - SZN-413, another candidate, is being developed for retinal vascular-associated diseases and has shown promise in preclinical models [12].